Prohibiting employers and health plan sponsors from choosing how they compensate pharmacy benefit companies (PBMs) based on the savings they provide (also termed “delinking”) will encourage drug manufacturers to raise their prices.
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on the Administration’s listening session on PBMs. “Today’s White House listening session on PBMs, where policymakers only hear from people and groups with vocal anti-PBM agendas, will
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement ahead of a U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) hearing on the high price of prescription drugs in the United States. “Lawmakers should challenge any
U.S. Senators Peter Welch (D-VT), Mike Braun (R-IN), and Amy Klobuchar (D-MN) recently introduced legislation that will crack down on drug companies’ patent abuse, specifically patent thickets. A companion bill in the House of Representatives was introduced by U.S. Representatives Jodey
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today announced that Waltz Health is joining the trade association as its newest member. “PCMA is proud to represent pharmacy benefit companies and the addition of Waltz Health to our membership
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with the list prices set by drug companies. The report also finds that “drug companies have
In case you missed it, former U.S. Senator Pat Toomey (R-PA) warns Republican policymakers against passing unvetted and disastrous policies targeting pharmacy benefits being debated in Washington, in a new op-ed published in The Washington Times. Toomey writes: “Giant, must-pass
Read Report
In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director and chief economist for the U.S. House Committee on Ways and Means, “Rebates and Drug
Thank you to all of our sponsors.If you are interested in becoming a sponsor, please contact Dylan Ashley. Partners Presidential Sponsors Executive Sponsors General Sponsors Corporate Benefactors Emerging Companies
©2024 PCMA. All Rights Reserved.
